Genome Insight – a precision healthcare solutions company promoting whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease – recently announced that it has closed a $23 million in a Series B-2 investment in its latest funding round. Samsung Venture Investment Corporation, Asan Foundation, SCL Group, and Ignite Innovation joined this funding round. Existing investors also participated in this round. This funding round follows a Series B investment in 2022 that also raised $23 million.
This funding round will support Genome Insight’s pursuit of bringing whole-genome-based precision diagnostics to routine clinical care. And earlier this year, the company announced the launch of CancerVision, a test that utilizes whole genome sequencing to offer precise, timely, and medical relevant information that assists in making individualized healthcare decisions in cancer.
CancerVision integrates advanced bioinformatics and computational techniques to determine whole-genome mutational profiles of individual cancer patients. The data is analyzed and curated for physicians in an easy-to-use format that captures the most relevant and actionable insights for each patient.
CancerVision was created to empower healthcare providers with the information necessary to make informed decisions tailored to an individual’s unique genomic profile. Whole genome sequencing (WGS) provides a more complete view (>99%) of a cancer’s genetic make-up than any other test currently available, including targeted panels and whole exome testing. And CancerVision is able to provide detailed information about genomic mutations and other biomarkers that may be driving a patient’s cancer. This information can support healthcare providers in identifying potential treatment approaches, such as targeted therapies and clinical trials, tailored to an individual’s specific cancer type and genetic makeup.
KEY QUOTES:
“Genomic data has the potential to unlock a new era in healthcare. We envision a future where genomic information is integral to standard patient care.”
— Young Seok Ju, the Founder and CEO at Genome Insight
